Dordaviprone (ONC201) clinical trials

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This study looks at a new drug, dordaviprone (ONC201), for a type of brain tumour called H3 K27M-mutant diffuse glioma. It aims to see if the drug, given after radiotherapy, can help people live longer and slow down the tumour's growth.